ASCO GU摘要标题公布！唐碧霞、盛锡楠教授研究分别入选全体大会和口头报告专场

2025年美国临床肿瘤学会泌尿生殖肿瘤研讨会(ASCO GU25）将于2月13-15号在美国旧金山举办。近期，ASCO GU官网公布了摘要标题。

本篇CCMTV泌尿频道整理了入选全体大会、口头报告专场的摘要标题，以飨读者。

Nectin-4靶向抗体偶联药物SHR-A2102治疗晚期或转移性尿路上皮癌患者的I期研究。

Nectin-4 targeted ADC, SHR-A2102, in patients with advanced or metastatic urothelial carcinoma: A phase 1 study.

报告人：唐碧霞

单位：北京大学肿瘤医院

WOLVERINE：基于X-MET合作组织的随机试验个体患者数据（IPD）的全球寡转移性前列腺癌（omPC）荟萃分析

World-wide oligometastatic prostate cancer (omPC) meta-analysis leveraging individual patient data (IPD) from randomized trials (WOLVERINE): An analysis from the X-MET collaboration.

报告人：Chad Tang

单位：The University of Texas MD Anderson Cancer Center

在177Lu-PSMA-617的PSMAfore研究中，基线与治疗期间循环肿瘤DNA（ctDNA）比例与转移性去势抵抗性前列腺癌（mCRPC）患者临床结局的相关性。

Association of baseline and on-treatment ctDNA fraction with clinical outcomes in patients with mCRPC in the PSMAfore study of 177Lu-PSMA-617

报告人：Johann De Bono

单位：The Royal Marsden NHS Foundation Trust

在ENZA-p（ANZUP 1901）试验中，针对高危、转移性、去势抵抗性前列腺癌患者，比较[¹⁷⁷Lu]Lu-PSMA-617联合恩扎卢胺vs恩扎卢胺单药治疗患者的总生存期和生活质量。

Overall survival and quality of life with [177Lu] Lu-PSMA-617 plus enzalutamide versus enzalutamide alone in poor-risk, metastatic, castration-resistant prostate cancer in ENZA-p (ANZUP 1901).

报告人：Louise Emmett

单位：St Vincent's Hospita

评估循环肾损伤标志物-1（KIM-1）作为晚期肾细胞癌（aRCC）预后和预测生物标志物的价值：CheckMate 214试验的事后分析

Evaluation of circulating kidney injury marker-1 (KIM-1) as a prognostic and predictive biomarker in advanced renal cell carcinoma (aRCC): Post-hoc analysis of CheckMate 214.

报告人：Wenxin Xu

单位：Dana-Farber Cancer Institute

HER2阳性肌层浸润性膀胱癌（MIBC）患者接受维迪西妥单抗联合围手术期特瑞普利单抗的新辅助治疗：来自II期RC48-C017试验的最新疗效和安全性结果。

Neoadjuvant treatment with disitamab vedotin plus perioperative toripalimab in patients with muscle-invasive bladder cancer (MIBC) with HER2 expression: Updated efficacy and safety results from the phase II RC48-C017 trial.

报告人：盛锡楠

单位：北京大学肿瘤医院

在III期TALAPRO-2试验中，未筛选的转移性去势抵抗性前列腺癌（mCRPC）患者接受他拉唑帕利（TALA）+恩扎卢胺（ENZA）作为一线治疗的最终总生存期（OS）。

Final overall survival (OS) with talazoparib (TALA) + enzalutamide (ENZA) as first-line treatment in unselected patients with metastatic castration-resistant prostate cancer (mCRPC) in the phase 3 TALAPRO-2 trial.

报告人：Neeraj Agarwal

单位：Huntsman Cancer Institute at the University of Utah

哪些转移性激素敏感性前列腺癌（mHSPC）患者从雄激素受体通路抑制剂（ARPIs）中获益更多？STOPCAP个体参与者数据（IPD）荟萃分析。

Which patients with metastatic hormone-sensitive prostate cancer (mHSPC) benefit more from androgen receptor pathway inhibitors (ARPIs)? STOPCAP meta-analyses of individual participant data (IPD).

报告人：David Fisher

单位：MRC Clinical Trials Unit at UCL

前列腺癌放疗剂量反应的基因特征预测指标：PORTOS在III期试验中的验证。

Gene signature predictor of dose-response to prostate radiation: Validation of PORTOS in phase III trials.

报告人：Shuang Zhao

单位：Department of Human Oncology, University of Wisconsin-Madison

高危前列腺癌（HR-PCa）中的根治性前列腺切除术（RP）与放射治疗（RT）：基于两项III期随机试验（RCTs）个体患者数据（IPD）的模拟随机对照比较。

Radical prostatectomy (RP) versus radiotherapy (RT) in high-risk prostate cancer (HR-PCa): Emulated randomized comparison with individual patient data (IPD) from two phase III randomized trials (RCTs).

报告人：Soumyajit Roy

单位：Rush University Medical Center

卡博替尼（C）联合纳武利尤单抗（N）和伊匹木单抗（I）治疗初治晚期肾细胞癌（aRCC）：COSMIC-313研究的最终结果。

Cabozantinib (C) in combination with nivolumab (N) and ipilimumab (I) in previously untreated advanced renal cell carcinoma (aRCC): Final results of COSMIC-313.

报告人：Laurence Albiges

单位：Institut Gustave Roussy, Université Paris Saclay

纳武利尤单抗联合卡博替尼（N+C）对比舒尼替尼（S）治疗初治晚期肾细胞癌（aRCC）：CheckMate 9ER试验的最终随访结果。

Nivolumab plus cabozantinib (N+C) vs sunitinib (S) for previously untreated advanced renal cell carcinoma (aRCC): Final follow-up results from the CheckMate 9ER trial.

报告人：Robert Motzer

单位：Memorial Sloan Kettering Cancer Center

KEYMAKER-U03 Substudy 03B：帕博利珠单抗（pembro）与靶向治疗联合用于晚期透明细胞肾细胞癌（ccRCC）的研究。

KEYMAKER-U03 Substudy 03B: Pembrolizumab (pembro) and targeted therapy combinations for advanced clear cell renal cell carcinoma (ccRCC).

报告人：Laurence Albiges

单位：Gustave Roussy, Paris-Saclay University

前瞻性COTRIMS试验（科隆转移性精原细胞瘤腹膜后淋巴结清扫术试验）的最终结果。

Prospective COTRIMS (Cologne trial of retroperitoneal lymphadectomy in metastatic seminoma) trial: Final results.

报告人：Axel Heidenreich

单位：Department of Urology, University Hospital of Cologne

纳武利尤单抗（NIVO）辅助疗法对比安慰剂（PBO）用于高危肌层浸润性尿路上皮癌（MIUC）：来自CheckMate 274研究的额外疗效结果，包括肌层浸润性膀胱癌（MIBC）患者的总生存期（OS）。

Adjuvant nivolumab (NIVO) vs placebo (PBO) for high-risk muscle-invasive urothelial carcinoma (MIUC): Additional efficacy outcomes including overall survival (OS) in patients (pts) with muscle-invasive bladder cancer (MIBC) from CheckMate 274.

报告人：Matthew Milowsky

单位：University of North Carolina School of Medicine

来自NIAGARA研究的额外疗效和安全性结果，以及对病理完全缓解（pCR）对长期结局影响的探索性分析。

Additional efficacy and safety outcomes and an exploratory analysis of the impact of pathological complete response (pCR) on long-term outcomes from NIAGARA.

报告人：Matthew Galsky

单位：Icahn School of Medicine at Mount Sinai

新辅助免疫治疗药物度伐利尤单抗（MEDI 4736）联合新辅助化疗（吉西他滨/顺铂或卡铂）在治疗可切除高危上尿路尿路上皮癌患者中的安全性和有效性。

Safety and efficacy of neoadjuvant immunotherapy with durvalumab (MEDI 4736) in combination with neoadjuvant chemotherapy (gemcitabine/cisplatin or carboplatin) in patients with operable high-risk upper tract urothelial carcinoma.

报告人：Nadine Houede

单位：Oncology Department, Montpellier University